Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1016/J.JTHO.2023.10.012 | ||||
| Año | 2024 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Introduction: The accurate assessment of nodal (N) status is crucial to the management and prognostication of nonmetastatic NSCLC. We sought to determine whether the current N descriptors should be maintained or revised for the upcoming ninth edition of the international TNM lung cancer staging system. Methods: Data were assembled by the International Association for the Study of Lung Cancer on patients with NSCLC, detailing both clinical and pathologic N status, with information about anatomical location and individual station-level identification. Survival was calculated by the Kaplan-Meier method and prognostic groups were assessed by a Cox regression analysis. Results: Data for clinical N and pathologic N status were available in 45,032 and 35,009 patients, respectively. The current N0 to N3 descriptors for both clinical N and pathologic N categories reflect prognostically distinct groups. Furthermore, single-station N2 involvement (N2a) exhibited a better prognosis than multistation N2 involvement (N2b) in both clinical and pathologic classifications, and the differences between all neighboring nodal subcategories were highly significant. The prognostic differences between N2a and N2b were robust and consistent across resection status, histologic type, T category, and geographic region. Conclusions: The current N descriptors should be maintained, with the addition of new subdescriptors to N2 for single-station involvement (N2a) and multiple-station involvement (N2b).
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Huang, James | Hombre |
Memorial Sloan-Kettering Cancer Center - Estados Unidos
Mem Sloan Kettering Canc Ctr - Estados Unidos |
| 2 | Osarogiagbon, Raymond U. | - |
Baptist Cancer Center - Estados Unidos
Baptist Canc Ctr - Estados Unidos |
| 3 | Giroux, Dorothy J. | Mujer |
Fred Hutchinson Cancer Center - Estados Unidos
Canc Res & Biostat - Estados Unidos |
| 4 | Nishimura, Katherine K. | Mujer |
Fred Hutchinson Cancer Center - Estados Unidos
Canc Res & Biostat - Estados Unidos |
| 5 | Bille, Andrea | Mujer |
Guy's Hospital - Reino Unido
King's College London - Reino Unido Guys Hosp - Reino Unido Kings Coll Univ - Reino Unido |
| 6 | Cardillo, Giuseppe | Hombre |
Azienda Ospedaliera San Camillo Forlanini - Italia
UniCamillus - Saint Camillus International University of Health and Medical Sciences - Italia Azienda Osped San Camillo Forlanini - Italia UniCamillus St Camillus Int Univ Hlth Sci - Italia |
| 7 | Detterbeck, Frank | Hombre |
Yale School of Medicine - Estados Unidos
YALE UNIV - Estados Unidos |
| 8 | Kernstine, Kemp | - |
UT Southwestern Medical School - Estados Unidos
Univ Texas Southwestern Med Ctr - Estados Unidos |
| 9 | Kim, Hong Kwan | - |
Samsung Medical Center, Sungkyunkwan University - Corea del Sur
Sungkyunkwan Univ - Corea del Sur |
| 10 | Lievens, Yolande | Mujer |
Universitair Ziekenhuis Gent - Bélgica
Ghent Univ Hosp - Bélgica Univ Ghent - Bélgica |
| 11 | Lim, Eric | Hombre |
Imperial College London - Reino Unido
Royal Brompton Hospital - Reino Unido Imperial Coll London - Reino Unido Royal Brompton Hosp - Reino Unido |
| 12 | Marom, Edith | - |
Tel Aviv University - Israel
Tel Aviv Univ - Israel |
| 13 | Prosch, Helmut | Hombre |
Allgemeines KrankenHaus Wien - Austria
Med Univ Vienna - Austria |
| 14 | Putora, Paul Martin | Hombre |
Kantonsspital St.Gallen - Suiza
University of Bern - Suiza Kantonsspital St Gallen - Suiza Univ Bern - Suiza |
| 15 | Rami-Porta, Ramon | Hombre |
Hospital Universitari de Bellvitge - España
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias - España Univ Barcelona - España Network Ctr Biomed Res Resp Dis CIBERES Lung Canc - España |
| 16 | Rice, David | - |
University of Texas Health Science Center at Houston - Estados Unidos
Univ Texas MD Anderson Canc Ctr - Estados Unidos |
| 17 | Rocco, Gaetano | Hombre |
Memorial Sloan-Kettering Cancer Center - Estados Unidos
Mem Sloan Kettering Canc Ctr - Estados Unidos |
| 18 | Rusch, Valerie W. | Mujer |
Memorial Sloan-Kettering Cancer Center - Estados Unidos
Mem Sloan Kettering Canc Ctr - Estados Unidos |
| 19 | Opitz, Isabelle | - |
UniversitatsSpital Zurich - Suiza
Univ Hosp Zurich - Suiza |
| 20 | Vasquez, Francisco Suarez | - |
Universidad de Los Andes, Chile - Chile
|
| 21 | Van Schil, Paul | Hombre |
Universitair Ziekenhuis Antwerpen - Bélgica
Antwerp Univ - Bélgica Universitair Ziekenhuis Gent - Bélgica |
| 22 | Jeffrey Yang, Chi Fu | - |
Massachusetts General Hospital - Estados Unidos
|
| 22 | Yang, Chi-Fu Jeffrey | - |
MASSACHUSETTS GEN HOSP - Estados Unidos
|
| 23 | Asamura, Hisao | Hombre |
Keio University School of Medicine - Japón
Keio Univ - Japón |
| 24 | Staging Prognostic Factors Comm | Corporación | |
| 25 | Advisory Boards | Corporación | |
| 26 | Participating Inst Lung Canc Domai | Corporación |
| Fuente |
|---|
| National Institutes of Health |
| Bristol-Myers Squibb |
| National Cancer Institute |
| Medtronic |
| AstraZeneca |
| Boehringer Ingelheim |
| Merck Sharp Dohme |
| Janssen |
| Siemens |
| Roche |
| Arthrex GmbH |
| Cancer Research United Kingdom |
| Bristol Myers Squibb Merck Sharp Dohme |
| Agradecimiento |
|---|
| ∗ CRISP is an AIO study (project no. AIO TRK-0315) under the medical leadership of the Executive Committee (Prof. F. Griesinger (Oldenburg), Prof. M. Thomas (Heidelberg), Dr. M. Sebastian (Frankfurt) and Dr. W. Eberhardt (Essen)). CRISP is conducted by AIO-Studien-gGmbH (sponsor) in cooperation with iOMEDICO (conception, project management, analysis). CRISP is supported by AstraZeneca GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Bristol Myers Squibb GmbH & Co. KGaA, Celgene GmbH, Lilly Deutschland GmbH, Merck Sharp & Dohme Sharp & Dohme GmbH, Novartis Pharma GmbH, Pfizer Pharma GmbH, Roche Pharma AG and Takeda Pharma Vertrieb GmbH & Co. KG. However, these companies have no input into or influence over data analysis, data interpretation, or writing of the manuscript. |
| ∗ CRISP is an AIO study (project no. AIO TRK-0315) under the medical leadership of the Executive Committee (Prof. F. Griesinger (Oldenburg), Prof. M. Thomas (Heidelberg), Dr. M. Sebastian (Frankfurt) and Dr. W. Eberhardt (Essen)). CRISP is conducted by AIO-Studien-gGmbH (sponsor) in cooperation with iOMEDICO (conception, project management, analysis). CRISP is supported by AstraZeneca GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Bristol Myers Squibb GmbH & Co. KGaA, Celgene GmbH, Lilly Deutschland GmbH, Merck Sharp & Dohme Sharp & Dohme GmbH, Novartis Pharma GmbH, Pfizer Pharma GmbH, Roche Pharma AG and Takeda Pharma Vertrieb GmbH & Co. KG. However, these companies have no input into or influence over data analysis, data interpretation, or writing of the manuscript. |
| Disclosure: Dr. Huang reports receiving grants from the National In-stitutes of Health/National Cancer Institute (NIH/NCI) Cancer Center Support Grant during the conduct of the study. Dr. Osarogiagbon re-ports receiving grants and personal fees from the NCI during the conduct of the study; personal fees from American Cancer Society, Biodesix, Genentech/Roche, LUNGevity Foundation, Tryptych Health-care Partners, AstraZeneca, GE Healthcare, Eli Lilly, Gilead Sciences, and P fizer outside the submitted work; has a patent lymph node specimen collection kit issued; has a patent method for collecting lymph nodes issued; is the Board Chair of Hope Foundation for Cancer Research (SouthWest Oncology Group) ; is a member of the Board of Scienti fic Advisors of the NCI; is a member of the steering committee of the National Lung Cancer Roundtable; is a participant of the sci-enti fic advisory board for the Lung Cancer Foundation of America, GO2 Foundation, Druckenmiller Center for Lung Cancer Research of the Memorial Sloan Kettering Cancer Center, and the LUNGevity Founda-tion; and is the founder of the Oncobox Devices, Inc. Dr. Lievens re-ports receiving grants or contracts from the European Union; is the chair of Health Economics of Radiation Oncology-Value Based HealthCare; and receives consulting fees from AstraZeneca. Dr. Lim reports receiving grants or contracts from AstraZeneca, Boehringer Ingelheim, Medela, Johnson and Johnson/Ethicon, Covidien/Medtronic, Guardant Health, Takeda, Lilly Oncology, and Bayer; consulting fees from Beigene, Roche, and Bristol-Myers Squibb; honorarium from Medela; has patents files outside of the scope of work; and has other financial/non financial interests outside of the scope of work. Dr. Marom reports receiving personal fees from Boehringer Ingelheim,r Merck Sharp & Dohme, and AstraZeneca outside the submitted work. Dr. Prosch reports receiving grants and contracts from Boehringer Ingelheim, AstraZeneca, and Siemens; honoraria from Boehringer Ingelheim, AstraZeneca, Siemens, Merck Sharp & Dohme, Bristol-Myers Squibb, Janssen, and Roche; and meeting support from Boehringer Ingelheim. Dr. Rusch reports receiving grants from Genelux; is a member of the Steering Committee of NIH Thoracic Malignancy; and receives non financial support from Cancer Research United Kingdom for the Mesothelioma and Radical Surgery II trial outside the submit-ted work. Dr. Opitz reports receiving institutional grants from Roche and Medtronic; is a member of the Speakers Bureau for Roche and AstraZeneca; is a member of the advisory board for AstraZeneca, Merck Sharp & Dohme, and Bristol-Myers Squibb; and has done proc-torship for Intuitive. Dr. Vasquez reports receiving grants and per-sonal fees from AstraZeneca and Roche outside of the submitted work. Dr. Van Schil reports receiving consulting fees from AstraZeneca, Roche, Bristol Myers Squibb Merck Sharp & Dohme, and Janssen; and honoraria from AstraZeneca, Roche, Bristo Myers Squibb, and Janssen outside of the submitted work. The remaining authors declare no con flict of interest. |